Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: Balance between oxidant stress and estrogen responsiveness

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Singh, Bhupendra ^a   Bhat, Nimee K ^a   Bhat, Hari K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTANE; CATALASE; ESTRADIOL; ESTROGEN RECEPTOR; GLUTATHIONE PEROXIDASE; PROGESTERONE RECEPTOR; SUPEROXIDE DISMUTASE; TAMOXIFEN; 8 ISOPROSTAGLANDIN E2; 8-HYDROXY-2'-DEOXYGUANOSINE; 8-ISOPROSTAGLANDIN E2; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DEOXYGUANOSINE; DRUG DERIVATIVE; ESTROGEN; ISOPROSTANE DERIVATIVE; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER INHIBITION; CELL PROLIFERATION; CIDEC GENE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME METABOLISM; ESTROGEN RESPONSIVE ELEMENT; FEMALE; LONG TERM CARE; MAOB1 GENE; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; RAT; ANIMAL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METABOLISM;

RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CATALASE; DEOXYGUANOSINE; DINOPROSTONE; ESTRADIOL; ESTROGENS; FEMALE; GLUTATHIONE PEROXIDASE; ISOPROSTANES; MAMMARY NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; RATS; SUPEROXIDE DISMUTASE; TAMOXIFEN;

EID: 80053136223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025125     Document Type: Article

References (68)

1. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV, (2003) Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci U S A 100: 3913-3918.
2. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, et al. (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766: 63-78.
3. IARC (1999) IARC monographs on the evaluation of carcinogenic risks to humans: hormonal contraception and postmenopausal hormone therapy. International Agency for Research on Cancer, Lyon 72: 474-530.
4. Cavalieri E, Rogan E, (2006) Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad Sci 1089: 286-301.
5. Clemons M, Goss P, (2001) Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285.
6. Liehr JG, Roy D, (1990) Free radical generation by redox cycling of estrogens. Free Radic Biol Med 8: 415-423.
7. Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, et al. (2008) Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 232: 78-85.
8. Mense SM, Singh B, Remotti F, Liu X, Bhat HK, (2009) Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats. Carcinogenesis 30: 1202-1208.
9. Singh B, Mense SM, Remotti F, Liu X, Bhat HK, (2009) Antioxidant butylated hydroxyanisole inhibits estrogen-induced breast carcinogenesis in female ACI rats. J Biochem Mol Toxicol 23: 202-211.
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388.
11. Wilson AJ, Baum M, Brinkley DM, Dossett JA, McPherson K, et al. (1985) Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. World J Surg 9: 756-764.
12. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758.
13. Group EBCTC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467.
14. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, et al. (2008) ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 68: 8908-8917.
15. Carthew P, Martin EA, White IN, De Matteis F, Edwards RE, et al. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res 55: 544-547.
16. Seoud MA, Johnson J, Weed JC Jr, (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 82: 165-169.
17. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339.
18. Riggins RB, Bouton AH, Liu MC, Clarke R, (2005) Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 71: 201-237.
19. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH, (2007) Pathways to tamoxifen resistance. Cancer Lett 256: 1-24.
20. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Poon GK, (1994) alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 54: 5518-5522.
21. Styles JA, Davies A, Lim CK, De Matteis F, Stanley LA, et al. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15: 5-9.
22. Lim CK, Yuan ZX, Lamb JH, White IN, De Matteis F, et al. (1994) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15: 589-593.
23. Crespi CL, Gonzalez FJ, Steimel DT, Turner TR, Gelboin HV, et al. (1991) A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing. Chem Res Toxicol 4: 566-572.
24. Han XL, Liehr JG, (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363.
25. Umemoto A, Monden Y, Suwa M, Kanno Y, Suzuki M, et al. (2000) Identification of hepatic tamoxifen-DNA adducts in mice: alpha-(N(2)-deoxyguanosinyl)tamoxifen and alpha-(N(2)-deoxyguanosinyl)tamoxifen N-oxide. Carcinogenesis 21: 1737-1744.
26. Li SA, Weroha SJ, Tawfik O, Li JJ, (2002) Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation. J Endocrinol 175: 297-305.
27. Arnerlov C, Emdin SO, Cajander S, Bengtsson NO, Tavelin B, et al. (2001) Intratumoral variations in DNA ploidy and s-phase fraction in human breast cancer. Anal Cell Pathol 23: 21-28.
28. Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, et al. (2002) Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog 33: 56-65.
29. Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, et al. (2000) Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci U S A 97: 2779-2784.
30. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL, (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis 18: 1595-1601.
31. Singh B, Mense SM, Bhat NK, Putty S, Guthiel WA, et al. (2010) Dietary quercetin exacerbates the development of estrogen-induced breast tumors in female ACI rats. Toxicol Appl Pharmacol 247: 83-90.
32. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, et al. (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A 101: 18123-18128.
33. Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, et al. (1997) Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 44: 65-74.
34. Weroha SJ, Li SA, Tawfik O, Li JJ, (2006) Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis 27: 491-498.
35. Kariagina A, Xie J, Leipprandt JR, Haslam SZ, (2010) Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers. Horm Cancer 1: 229-244.
36. Mukherjee S, Conrad SE, (2005) c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 280: 17617-17625.
37. Patel MM, Bhat HK, (2004) Differential oxidant potential of carcinogenic and weakly carcinogenic estrogens: Involvement of metabolic activation and cytochrome P450. J Biochem Mol Toxicol 18: 37-42.
38. Cavalieri EL, Rogan EG, (2004) A unifying mechanism in the initiation of cancer and other diseases by catechol quinones. Ann N Y Acad Sci 1028: 247-257.
39. Li JJ, Li SA, (1987) Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 46: 1858-1863.
40. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A, (1986) Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 24: 353-356.
41. Yager JD, (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr pp. 67-73.
42. Vitseva O, Flockhart DA, Jin Y, Varghese S, Freedman JE, (2005) The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther 312: 1144-1150.
43. Mobley JA, Brueggemeier RW, (2004) Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 25: 3-9.
44. Montano MM, Chaplin LJ, Deng H, Mesia-Vela S, Gaikwad N, et al. (2007) Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene 26: 3587-3590.
45. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, et al. (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23: 1897-1901.
46. Dehal SS, Kupfer D, (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57: 3402-3406.
47. Desta Z, Ward BA, Soukhova NV, Flockhart DA, (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062-1075.
48. Hu Y, Dehal SS, Hynd G, Jones GB, Kupfer D, (2003) CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes. Xenobiotica 33: 141-151.
49. Krueger SK, Vandyke JE, Williams DE, Hines RN, (2006) The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab Rev 38: 139-147.
50. Parte P, Kupfer D, (2005) Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33: 1446-1452.
51. Lewis JS, Jordan VC, (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591: 247-263.
52. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, et al. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937.
53. Lundholm L, Putnik M, Otsuki M, Andersson S, Ohlsson C, et al. (2008) Effects of estrogen on gene expression profiles in mouse hypothalamus and white adipose tissue: target genes include glutathione peroxidase 3 and cell death-inducing DNA fragmentation factor, alpha-subunit-like effector A. J Endocrinol 196: 547-557.
54. Zhang Z, Chen K, Shih JC, Teng CT, (2006) Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors. Mol Endocrinol 20: 1547-1561.
55. von Mach-Szczypinski J, Stanosz S, Sieja K, Stanosz M, (2009) Metabolism of histamine in tissues of primary ductal breast cancer. Metabolism 58: 867-870.
56. Inohara N, Koseki T, Chen S, Wu X, Nunez G, (1998) CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J 17: 2526-2533.
57. Liang L, Zhao M, Xu Z, Yokoyama KK, Li T, (2003) Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector family. Biochem J 370: 195-203.
58. Clark AS, West K, Streicher S, Dennis PA, (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717.
59. Lee YJ, Galoforo SS, Berns CM, Chen JC, Davis BH, et al. (1998) Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. J Biol Chem 273: 5294-5299.
60. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935.
61. Dhandapani KM, Brann DW, (2002) Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 67: 1379-1385.
62. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, et al. (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104: 719-730.
63. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER, (2002) Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 277: 50768-50775.
64. Han X, Liehr JG, (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15: 997-1000.
65. Bhat HK, Hacker HJ, Bannasch P, Thompson EA, Liehr JG, (1993) Localization of estrogen receptors in interstitial cells of hamster kidney and in estradiol-induced renal tumors as evidence of the mesenchymal origin of this neoplasm. Cancer Res 53: 5447-5451.
66. Marklund S, (1980) Distribution of CuZn superoxide dismutase and Mn superoxide dismutase in human tissues and extracellular fluids. Acta Physiol Scand Suppl 492: 19-23.
67. Bhat HK, Epelboym I, (2004) Suppression of calbindin D28K in estrogen-induced hamster renal tumors. J Steroid Biochem Mol Biol 92: 391-398.
68. Huang X, Powell J, Mooney LA, Li C, Frenkel K, (2001) Importance of complete DNA digestion in minimizing variability of 8-oxo-dG analyses. Free Radic Biol Med 31: 1341-1351.